Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of eribulin mesylate in pediatric relapsed or refractory sarcomas
2018-001282-17Phase 2
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eribulin in rhabdomyosarcoma (RMS), soft tissue sarcoma (STS) and Ewing sarcoma, sponsored by Eisai Co., Ltd. Primary endpoint: Objective response.
02
Drugs
eribulin
03
Conditions
rhabdomyosarcoma (RMS)soft tissue sarcoma (STS)Ewing sarcoma
Beyond the preview
Go deeper on 2018-001282-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001282-17.